Veru (VERU) AI Stock Analysis

• Market Cap: $40.61M
• Dividend Yield: N/A
• Average Volume (3M): 129.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: -100.00%
• EPS Growth: 55.10%
• Country: US
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 16,050,320
• 10 Day Avg. Volume: 115,470
• 30 Day Avg. Volume: 129,520
• PEG Ratio: 0.05
• Price to Book (P/B): 3.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -148.03
• Enterprise Value/Ebitda: -1.45
• 1Y Price Target: $25.00
• Price Target Upside: 1016.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(11.61% Upside)

VERU scores low primarily due to weak financial performance (zero revenue in 2025, persistent losses, and ongoing cash burn), reinforced by a weak technical setup with the stock below key moving averages and negative MACD. Offsetting these risks, the latest earnings call provided encouraging clinical and regulatory updates for the obesity program, supporting a modest uplift to the overall score.

Positive Factors

Phase IIb clinical efficacy

Robust Phase IIb efficacy on lean-mass preservation and incremental fat loss supports a differentiated clinical profile versus GLP-1s. That durable clinical signal raises the probability of a viable regulatory label or partnership, strengthening long-term commercial potential.

Regulatory clarity from FDA

Clear FDA guidance reduces development and design uncertainty, enabling focused pivotal plans and more predictable timelines. That structural clarity lowers execution risk, improves trial planning and investor/partner confidence over a multi-month horizon.

Lower leverage vs prior years

Material reduction in debt-to-equity meaningfully lowers financial distress risk and interest burden. Structurally, lower leverage preserves operational flexibility for R&D spend and partnering negotiations, improving the firm's ability to execute development programs.

Negative Factors

Revenue collapse to zero

Loss of recurring product revenue removes self-funding capacity and shifts the company to a pure development funding model. Over months, this heightens reliance on external capital, complicates long-term planning, and raises execution risk for pivotal trials.

Consistent negative cash flow and cash burn

Persistent negative operating and free cash flow means the company cannot self-fund development. Structurally, this necessitates repeated financings that can dilute equity, delay programs if markets tighten, and constrain long-term R&D continuity.

Erosion of equity and sustained losses

Declining shareholder equity and repeated net losses reflect ongoing value erosion and weak operating returns. Over the medium term, this undermines bargaining power with partners, limits strategic options, and increases the risk of unfavorable financing terms.

Veru Business Overview & Revenue Model

Company Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

How the Company Makes Money

Veru generates revenue primarily through the commercialization of its pharmaceutical products, which includes sales from its approved therapies. The company also engages in research and development partnerships with other pharmaceutical companies, which can provide additional funding and resources in exchange for shared rights to new drugs. Additionally, Veru may receive milestone payments and royalties from licensing agreements related to its drug candidates. The ongoing development of its pipeline products and successful clinical trials are critical to expanding its revenue streams.

Veru Financial Statement Overview

Summary

Overall fundamentals are weak: revenue dropped to zero in 2025, profitability remains meaningfully negative, and operating/free cash flow are negative every year with continued cash burn. The main offset is improved leverage (lower debt-to-equity) versus prior years, but shrinking equity and sustained losses keep financial risk elevated.

Income Statement

Fundamentals are weak and volatile. Annual revenue fell to zero in 2025 after ~$16.9M in 2024 (a -100% drop), indicating a major commercial disruption or transition. Profitability remains deeply negative across most years: net losses were very large in 2022–2024 (with especially severe losses in 2023), and while 2025 EBIT turned positive, net income stayed meaningfully negative. The only clear profitable year in the dataset was 2021, highlighting inconsistent earnings power and limited margin stability.

Balance Sheet

Balance sheet risk looks moderate and has improved recently. Leverage is currently low with debt-to-equity around 0.17 in 2025 versus higher levels in 2023–2024, and total debt has come down materially year over year. However, equity has also declined sharply since 2021–2022, and returns on equity are consistently negative from 2022 through 2025, reflecting ongoing value erosion from sustained losses.

Cash Flow

Cash generation is a key weakness. Operating cash flow and free cash flow are negative every year shown, including a sizable cash burn in 2025 (roughly -$30M operating and free cash flow). While cash burn improved versus 2023’s extremely large outflow, it worsened again versus 2024, suggesting the company has not yet reached a stable, self-funding operating model and may remain dependent on external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	16.89M	16.30M	39.35M	61.26M
Gross Profit	-152.10K	-152.10K	5.85M	7.57M	30.59M	47.93M
EBITDA	-15.53M	-15.53M	-36.20M	-89.98M	-79.23M	9.75M
Net Income	-22.73M	-22.73M	-37.80M	-93.15M	-83.78M	7.39M
Balance Sheet
Total Assets	29.84M	29.84M	60.42M	50.02M	135.36M	178.15M
Cash, Cash Equivalents and Short-Term Investments	18.32M	18.32M	24.92M	9.63M	80.19M	122.36M
Total Debt	3.12M	3.12M	13.86M	14.41M	15.88M	13.74M
Total Liabilities	11.50M	11.50M	28.10M	30.34M	52.56M	25.85M
Stockholders Equity	18.33M	18.33M	32.32M	19.68M	82.80M	152.29M
Cash Flow
Free Cash Flow	-30.04M	-30.04M	-21.84M	-88.68M	-48.24M	-15.95M
Operating Cash Flow	-30.04M	-30.04M	-21.68M	-88.01M	-47.51M	-15.57M
Investing Cash Flow	25.14M	25.14M	146.21K	6.33M	4.27M	14.62M
Financing Cash Flow	-4.22M	-4.22M	36.83M	11.11M	1.07M	109.72M

Veru Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERU, the sentiment is Negative. The current price of 2.24 is below the 20-day moving average (MA) of 2.52, below the 50-day MA of 2.44, and below the 200-day MA of 3.99, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 38.82 is Neutral, neither overbought nor oversold. The STOCH value of 18.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERU.

Veru Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INMB	51 Neutral	$40.41M	-0.66	-155.77%	―	19.05%	2.01%
KPTI	48 Neutral	$115.35M	-0.42	―	―	-3.98%	-29.94%
VERU	45 Neutral	$40.61M	-1.76	-61.92%	―	-100.00%	55.10%
CELU	44 Neutral	$34.61M	-0.35	―	―	-15.81%	-113.06%
CUE	42 Neutral	$28.21M	-0.69	-195.19%	―	-25.51%	49.72%

Veru Corporate Events

Veru Announces Public Offering to Raise $23.4 Million

On October 30, 2025, Veru Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering of 8,400,000 shares of its common stock, along with Series A and B warrants, expected to raise approximately $23.4 million. The proceeds will primarily fund the development of enobosarm, focusing on the Phase 2b PLATEAU clinical study, and for general corporate purposes. The offering is expected to close on or about October 31, 2025, subject to customary conditions, and aims to strategically position Veru in the biopharmaceutical market by advancing its clinical pipeline.

The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.